Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants
Ann‐Kathrin Reuschl, Lucy Thorne, Matthew V. X. Whelan, Roberta Ragazzini, Wilhelm Furnon, Vanessa M. Cowton, Giuditta De Lorenzo, Dejan Mesner, Jane Turner, Giulia Dowgier, Nathasha Bogoda, Paola Bonfanti, Massimo Palmarini, Arvind H. Patel, Clare Jolly, Greg J. Towers
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) human adaptation resulted in distinct lineages with enhanced transmissibility called variants of concern (VOCs). Omicron is the first VOC to evolve distinct globally dominant subvariants. Here we compared their replication in human cell lines and primary airway cultures and measured host responses to infection. We discovered that subvariants BA.4 and BA.5 have improved their suppression of innate immunity when compared with earlier subvariants BA.1 and BA.2. Similarly, more recent subvariants (BA.2.75 and XBB lineages) also triggered reduced innate immune activation. This correlated with increased expression of viral innate antagonists Orf6 and nucleocapsid, reminiscent of VOCs Alpha to Delta. Increased Orf6 levels suppressed host innate responses to infection by decreasing IRF3 and STAT1 signalling measured by transcription factor phosphorylation and nuclear translocation. Our data suggest that convergent evolution of enhanced innate immune antagonist expression is a common pathway of human adaptation and link Omicron subvariant dominance to improved innate immune evasion.